Is weight loss beneficial for reduction of morbidity and mortality? What is the controversy about?

@article{Nilsson2008IsWL,
  title={Is weight loss beneficial for reduction of morbidity and mortality? What is the controversy about?},
  author={Peter Nilsson},
  journal={Diabetes care},
  year={2008},
  volume={31 Suppl 2},
  pages={S278-83}
}
The increase of obesity and type 2 diabetes on a global scale has increased the interest in how to counteract this epidemic. Improved lifestyle in general is a fundamental approach, but other remedies such as specific weight reduction or diabetes preventive drugs and surgery have also been tested. One problem to understand is what really happens after weight loss. Ongoing studies will try to address this question, such as the Swedish Obese Subjects (SOS) surgery study, the Look AHEAD (Action… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 46 references

Rosiglitazone reduces carotid intima-media thickness progression over 1 year in patients with type 2 diabetes but not in non-diabetic people who have insulin resistance alone

  • B Hedblad, PM Nilsson, A Zambanini, G Berglund
  • J Intern Med
  • 2007
1 Excerpt

DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medica

  • Investigators Trial, HC Gerstein, +11 authors RR Holman
  • Lancet 368:1096–1105,
  • 2006

Effects of the cannabinoid1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients : 1 - year experience from the RIOEurope study

  • LF VanGaal, AM Rissanen, AJ Scheen, O Ziegler, S Rossner
  • Lancet
  • 2006

Similar Papers

Loading similar papers…